Balance Sheet Information (Tables)
|
3 Months Ended |
Mar. 31, 2024 |
|---|
| Balance Sheet Related Disclosures [Abstract] |
|
| Schedule of of cash and cash equivalents and restricted cash |
A summary of cash and cash equivalents and restricted cash is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2024 |
|
December 31, 2023 |
| Cash and Cash Equivalents |
$ |
31,276,330 |
|
|
$ |
2,454,684 |
|
| Restricted Cash, Non-current |
4,084 |
|
|
4,267 |
|
| Total Cash, Cash Equivalents and Restricted Cash |
$ |
31,280,414 |
|
|
$ |
2,458,951 |
|
|
| Schedule of restricted cash |
A summary of cash and cash equivalents and restricted cash is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2024 |
|
December 31, 2023 |
| Cash and Cash Equivalents |
$ |
31,276,330 |
|
|
$ |
2,454,684 |
|
| Restricted Cash, Non-current |
4,084 |
|
|
4,267 |
|
| Total Cash, Cash Equivalents and Restricted Cash |
$ |
31,280,414 |
|
|
$ |
2,458,951 |
|
|
| Schedule of prepaid expenses and other current assets |
Prepaid expenses and other current assets consist of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2024 |
|
December 31, 2023 |
| Prepaid General and Administrative |
$ |
109,395 |
|
|
$ |
73,109 |
|
| Prepaid Insurance |
72,872 |
|
|
123,807 |
|
| Prepaid Research and Development |
24,404 |
|
|
23,066 |
|
| Other |
— |
|
|
13,400 |
|
| Total Prepaid Expenses and Other Current Assets |
$ |
206,671 |
|
|
$ |
233,382 |
|
|
| Schedule of accrued expenses |
Accrued expenses consist of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2024 |
|
December 31, 2023 |
| Payroll and Benefits |
$ |
972,562 |
|
|
$ |
875,254 |
|
| Professional Fees |
57,575 |
|
|
43,387 |
|
| Clinical Trials |
120,135 |
|
|
397,465 |
|
| Other |
71,806 |
|
|
64,560 |
|
| Total Accrued Expenses |
$ |
1,222,078 |
|
|
$ |
1,380,666 |
|
|